We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 23, 2020

Preoperative Cisplatin vs Paclitaxel in Triple-Negative Breast Cancer

Annals of Oncology


Additional Info

Annals of Oncology
TBCRC 030: A Phase II Study of Preoperative Cisplatin vs. Paclitaxel in Triple-Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Ann. Oncol 2020 Aug 13;[EPub Ahead of Print], EL Mayer, V Abramson, R Jankowitz, C Falkson, PK Marcom, T Traina, L Carey, M Rimawi, J Specht, K Miller, V Stearns, N Tung, C Perou, AL Richardson, K Componeschi, L Trippa, Z Tan-Wasielewski, K Timms, I Krop, AC Wolff, EP Winer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading